## Abstract We report our longβterm experience using enteral levodopa infusions in 22 patients with Parkinson's disease and severe motor fluctuations. Amelioration of intractable dyskinesias was the most important factor that determined whether patients chose to continue using the infusion pump sys
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease
β Scribed by John G. Nutt; Julie H. Carter; Eric S. Lea; William R. Woodward
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 975 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The cause of motor fluctuations occurring during constantβrate levodopa infusions is unknown. We examined whether known pharmacokinetic factors could explain the fluctuations and looked for clues to pharmacodynamic causes. Eleven subjects with stage IIIβV Parkinson's disease (PD) and a fluctuating response to levodopa underwent constantβrate infusions for 36β110 h. Levodopa, 3βOβmethyldopa (3βOMD), and plasma large neutral amino acids (LNAAs) were measured at 2β to 6βh intervals and PD was monitored hourly from 07:00 to 22:00 h with tapping speed. Ten subjects had motor fluctuations during the infusions. Zero to 68% of the variability of tapping speed could be explained by variation in plasma LNAA concentrations in individual subjects. Flutuations occurred more commonly later in the day, which may be related to the tendencey fo LNAAs to increase during the day. Motor fluctuations were not associated with minor variations in levodopa or 3βOMD concentrations. Fluctuations during constant infusions were more marked in patients using larger daily doses of oral levodopa; severity of PD did not predict fluctuations during the infusions. There was no trend for fluctuations or dyskinesia to decrease or increase during several days of constantβrate levodopa infusion. A portion of motor fluctuations occurring during constant levodopa infusions can be explained by peripheral pharmacokinetic mechanisms. Fluctuations are more prominent in subjects who have taken larger daily doses of levodopa, implicating pharmacodynamic factors as well.
π SIMILAR VOLUMES
## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KWβ6002) is an adenosine A~2A~ receptor a